# Eureka Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eureka-therapeutics

- Industry: Biotechnology
- Headquarters: Emeryville, US
- Website: www.eurekainc.com
- Total disclosed funding: $57M
- Latest round: Series D (May 23, 2017)
- Investors on record: 7

## About

Based in California, US, and founded in 2006, Eureka Therapeutics, Inc. is a clinical-stage biotechnology company. Dr. Cheng Liu is the founder and current President and CEO of the company. In December 2019, Eureka Therapeutics, Inc. raised USD 45 million in Series E funding led by new investor Lyell Immunopharma, Inc., with participation from other unspecified investors.

The company focuses on creating new T cell treatments for cancer treatment. Its main technology focuses on the discovery and development of potentially safer and more effective T cell treatments for the treatment of solid tumors and hematologic malignancies using its patented ARTEMIS AbTCR T cell receptor platform and E-ALPHA antibody discovery platform.

Following the Series E funding closed in March 2020, the company will use the proceeds to advance its proprietary TCR-mimic and antibody-TCR ARTEMIS programs, including Eureka’s anti-AFP ARTEMIS Phase I/II clinical trial in the United States for the treatment of hepatocellular carcinoma (HCC).

## Funding rounds

- Series D, May 23, 2017, $33M — GP Capital, Acorn Pacific Ventures
- Series C, Aug 20, 2014, $21M — Harbinger Venture Capital, Suma Capital, Acorn Campus Ventures, Majuven, Yuanfu Capital
- Series B, Oct 28, 2008, $1.7M — Acorn Campus Ventures
- Series A, Jun 11, 2007, $1.2M — Acorn Campus Ventures

## Investors

- Acorn Campus Ventures (https://capitalatlas.ai/funds/acorn-campus-ventures) — Series A, Series B, Series C
- Harbinger Venture Capital (https://capitalatlas.ai/funds/harbinger-venture-capital) — Series C
- Suma Capital (https://capitalatlas.ai/funds/suma-capital) — Series C
- Majuven (https://capitalatlas.ai/funds/majuven) — Series C
- Yuanfu Capital (https://capitalatlas.ai/funds/yuanfu-capital) — Series C
- GP Capital (https://capitalatlas.ai/funds/gp-capital) — Series D
- Acorn Pacific Ventures (https://capitalatlas.ai/funds/acorn-pacific-ventures) — Series D